search
Back to results

The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

Primary Purpose

Antineutrophil Cytoplasmic Antibody Associated Vasculitis

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
STSA-1002 subcutaneous injection
STSA-1002 subcutaneous injection
Sponsored by
Staidson (Beijing) Biopharmaceuticals Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Antineutrophil Cytoplasmic Antibody Associated Vasculitis

Eligibility Criteria

21 Years - 57 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Healthy subjects, aged ≥ 21 but ≤ 57, male and female. Weight: 50-93 kg; Body mass index (BMI): 21~31 kg/m2, inclusive. Subjects (including their partners) agree to take highly effective contraceptive measures during the study, and they have no birth plan or sperm donation plan within 6 months after the end of the study. Female and/or male subjects those meet the below criteria: If a female subject of childbearing potential - agrees to use one of the accepted contraceptive regimens from at least 30 days prior to administration of IMP, during the study, and for at least 6 months after the administration of IMP. An acceptable method of contraception includes one of the following: Abstinence from heterosexual intercourse, if it is the preferred and usual lifestyle choice of the subject. Additionally, it should be noted that periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) is not an acceptable method of birth control; Hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch); Intrauterine device (with or without hormones) OR agrees to use a double barrier method (e.g. condom and spermicide) during the study and for at 6 months after the administration of IMP. If a female subject of non-childbearing potential - should have been surgically sterilized at least 6 months before screening (i.e. has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation/occlusion) or in the postmenopausal state (at least 1 year without menses), as confirmed by Follicle-stimulating hormone (FSH) levels (≥ 40 mIU/mL). A male subject that engages in sexual activity that has the risk of pregnancy must agree to use a double barrier method (e.g. condom and spermicide) and agree to not donate sperm during the study and for at least 6 months after the administration of IMP. Medical histories, physical examinations, laboratory examinations and study-related examinations and tests of the subjects show normal results or mild abnormalities with no clinical significance before enrollment, and the Investigator judges that they are eligible. Subjects are aware of the risks of the study, and voluntarily participate in the clinical study and sign an informed consent form (ICF). Exclusion Criteria: History of cardiovascular, respiratory, kidney, liver, metabolism, endocrine, gastrointestinal, blood, nerve, skin and mental illness, cancer or other major disease that in the judgment of the Investigator might put the subject as risk on this study. History of tuberculosis or a recent history of infection within the past 4 weeks. History of recurrent infections. Presence of clinically significant laboratory values during the screening period, as defined by an Investigator. Presence of clinically significant vital signs values or of electrocardiogram (ECG) abnormalities during the screening period, as defined by an Investigator. Subjects who have autoimmune disease or immunodeficiency, or have a family history of related diseases. Subjects who have history of hypersensitivity or clinically significant allergic reaction to any drug, biologic, food or vaccine. Positive screening test results for human immunodeficiency virus (HIV-1/HIV-2) antibodies, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCVAb). Subjects who have received treatment with an investigational drug within 30 days or 5 times the half-life (whichever is longer) prior to screening. Subjects who have participated in any vaccine clinical study or have received any live vaccine within 3 months prior to the IMP administration or plan to receive live vaccines during the study period, and subjects who have received inactivated or attenuated vaccines 28 days prior to the IMP administration or plan to receive inactivated or attenuated vaccines within 2 months after the end of the study. If the subject has received any SARS-CoV-2 vaccine prior to screening, enrollment must be delayed until the biologic impact of the vaccine is stabilized, as determined by discussion between the investigator and the sponsor. Subjects who have taken drugs that may affect immune function within 6 months before screening, have received any monoclonal antibody or biological agent for treatment (for any illness) within the previous 3 months, and have previous treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals) within 7 days prior to IMP administration. Subjects whose daily consumption of coffee, tea and/or cola is more than 750 mL or 25 fl. oz in the last 30 days before enrollment. Subjects who have a positive urine alcohol test or urine drug test before enrollment. Subjects who have nicotine consumption (e.g., smoking, nicotine patch, nicotine chewing gum, or electronic cigarettes) within 3 months prior to screening and inability to refrain from nicotine consumption from screening until end of study. Female subjects who are pregnant or breastfeeding during the screening period and on admission. Subjects whose daily consumption of alcohol at the time of screening or at any time within the prior 2 months is more than 2 standard drinks, where 1 standard drink = 355 mL or 12 oz (1 can) of regular-strength (5%) beer; 150 mL or 5 oz wine; 45 mL or 1.5 oz liquor/spirits (40%). History of drug or alcohol abuse (as defined by the investigator), or addiction within 1 year prior to screening. Subjects who have undergone major surgery within 6 months of screening, or who will have elective surgery that will occur during the study period. Subjects who have donated either more than approximately 500 mL of blood (exclusive plasma donation) within 56 days (8 weeks) prior to screening or any plasma within 7 days (1 week) prior to screening. Subjects fails or is unwilling to abstain from strenuous physical activities for at least 48 hours prior to IMP administration and throughout the study. Subjects with any factors that would, in the Investigator's judgment, preclude them from participating in this study.

Sites / Locations

  • AltaSciences Clinical Kansas, Inc

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

STSA-1002 subcutaneous injection: dose 1 (First cohort)

STSA-1002 subcutaneous injection: dose 2 (Second cohort)

Arm Description

Outcomes

Primary Outcome Measures

Number of treatment-related adverse events as assessed by toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials
To evaluate the safety and tolerability of STSA-1002 subcutaneous injection in healthy adult subjects
Abnormal clinical laboratory values as assessed by toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (blood hematology, blood chemistry, urinalysis, etc.)
To evaluate the safety and tolerability of STSA-1002 subcutaneous injection in healthy adult subjects
Abnormal vital signs as assessed by toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (body temperature, pulse rate, blood pressure and respiratory rate)
To evaluate the safety and tolerability of STSA-1002 subcutaneous injection in healthy adult subjects
Abnormal physical examination
To evaluate the safety and tolerability of STSA-1002 subcutaneous injection in healthy adult subjects
Abnormal electrocardiogram (ECG): heart rate, PR and QT intervals, QTcF and QRS duration
To evaluate the safety and tolerability of STSA-1002 subcutaneous injection in healthy adult subjects
Maximum plasma concentration (Cmax)
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
Time of maximum concentration (Tmax)
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
elimination half-life (t1/2)
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
elimination rate constant of plasma drug concentration in terminal phase (λz)
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
last measurable concentration (Clast)
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
mean residence time (MRT)
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
clearance (CL)
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
apparent volume of distribution (Vz)
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects

Secondary Outcome Measures

Change from baseline in concentration of free C5a
To evaluate the pharmacodynamics (PD) characteristics and immunogenicity of STSA-1002 subcutaneous injection in healthy subjects
anti-drug antibody
To evaluate the pharmacodynamics (PD) characteristics and immunogenicity of STSA-1002 subcutaneous injection in healthy subjects

Full Information

First Posted
December 23, 2022
Last Updated
May 24, 2023
Sponsor
Staidson (Beijing) Biopharmaceuticals Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT05702983
Brief Title
The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects
Official Title
An Open-label, Single-ascending Dose, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STSA-1002 Subcutaneous Injection in Healthy Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
January 31, 2023 (Actual)
Primary Completion Date
April 11, 2023 (Actual)
Study Completion Date
April 24, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Staidson (Beijing) Biopharmaceuticals Co., Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
An Open-label, Single-ascending dose, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STSA-1002 Subcutaneous Injection in Healthy Subjects

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Antineutrophil Cytoplasmic Antibody Associated Vasculitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
STSA-1002 subcutaneous injection: dose 1 (First cohort)
Arm Type
Experimental
Arm Title
STSA-1002 subcutaneous injection: dose 2 (Second cohort)
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
STSA-1002 subcutaneous injection
Intervention Description
Subjects will receive a single low dose on day 1 following protocol requirements.
Intervention Type
Drug
Intervention Name(s)
STSA-1002 subcutaneous injection
Intervention Description
Subjects will receive a single high dose on day 1 following protocol requirements.
Primary Outcome Measure Information:
Title
Number of treatment-related adverse events as assessed by toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials
Description
To evaluate the safety and tolerability of STSA-1002 subcutaneous injection in healthy adult subjects
Time Frame
50 days
Title
Abnormal clinical laboratory values as assessed by toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (blood hematology, blood chemistry, urinalysis, etc.)
Description
To evaluate the safety and tolerability of STSA-1002 subcutaneous injection in healthy adult subjects
Time Frame
50 days
Title
Abnormal vital signs as assessed by toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (body temperature, pulse rate, blood pressure and respiratory rate)
Description
To evaluate the safety and tolerability of STSA-1002 subcutaneous injection in healthy adult subjects
Time Frame
50 days
Title
Abnormal physical examination
Description
To evaluate the safety and tolerability of STSA-1002 subcutaneous injection in healthy adult subjects
Time Frame
50 days
Title
Abnormal electrocardiogram (ECG): heart rate, PR and QT intervals, QTcF and QRS duration
Description
To evaluate the safety and tolerability of STSA-1002 subcutaneous injection in healthy adult subjects
Time Frame
50 days
Title
Maximum plasma concentration (Cmax)
Description
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
Time Frame
Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
Title
area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)
Description
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
Time Frame
Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
Title
area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)
Description
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
Time Frame
Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
Title
Time of maximum concentration (Tmax)
Description
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
Time Frame
Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
Title
elimination half-life (t1/2)
Description
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
Time Frame
Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
Title
elimination rate constant of plasma drug concentration in terminal phase (λz)
Description
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
Time Frame
Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
Title
last measurable concentration (Clast)
Description
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
Time Frame
Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
Title
mean residence time (MRT)
Description
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
Time Frame
Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
Title
clearance (CL)
Description
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
Time Frame
Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
Title
apparent volume of distribution (Vz)
Description
To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 subcutaneous injection in healthy adult subjects
Time Frame
Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
Secondary Outcome Measure Information:
Title
Change from baseline in concentration of free C5a
Description
To evaluate the pharmacodynamics (PD) characteristics and immunogenicity of STSA-1002 subcutaneous injection in healthy subjects
Time Frame
Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
Title
anti-drug antibody
Description
To evaluate the pharmacodynamics (PD) characteristics and immunogenicity of STSA-1002 subcutaneous injection in healthy subjects
Time Frame
Pre-dose; after dose 336hours, 840hours, 1176hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
57 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy subjects, aged ≥ 21 but ≤ 57, male and female. Weight: 50-93 kg; Body mass index (BMI): 21~31 kg/m2, inclusive. Subjects (including their partners) agree to take highly effective contraceptive measures during the study, and they have no birth plan or sperm donation plan within 6 months after the end of the study. Female and/or male subjects those meet the below criteria: If a female subject of childbearing potential - agrees to use one of the accepted contraceptive regimens from at least 30 days prior to administration of IMP, during the study, and for at least 6 months after the administration of IMP. An acceptable method of contraception includes one of the following: Abstinence from heterosexual intercourse, if it is the preferred and usual lifestyle choice of the subject. Additionally, it should be noted that periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) is not an acceptable method of birth control; Hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch); Intrauterine device (with or without hormones) OR agrees to use a double barrier method (e.g. condom and spermicide) during the study and for at 6 months after the administration of IMP. If a female subject of non-childbearing potential - should have been surgically sterilized at least 6 months before screening (i.e. has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation/occlusion) or in the postmenopausal state (at least 1 year without menses), as confirmed by Follicle-stimulating hormone (FSH) levels (≥ 40 mIU/mL). A male subject that engages in sexual activity that has the risk of pregnancy must agree to use a double barrier method (e.g. condom and spermicide) and agree to not donate sperm during the study and for at least 6 months after the administration of IMP. Medical histories, physical examinations, laboratory examinations and study-related examinations and tests of the subjects show normal results or mild abnormalities with no clinical significance before enrollment, and the Investigator judges that they are eligible. Subjects are aware of the risks of the study, and voluntarily participate in the clinical study and sign an informed consent form (ICF). Exclusion Criteria: History of cardiovascular, respiratory, kidney, liver, metabolism, endocrine, gastrointestinal, blood, nerve, skin and mental illness, cancer or other major disease that in the judgment of the Investigator might put the subject as risk on this study. History of tuberculosis or a recent history of infection within the past 4 weeks. History of recurrent infections. Presence of clinically significant laboratory values during the screening period, as defined by an Investigator. Presence of clinically significant vital signs values or of electrocardiogram (ECG) abnormalities during the screening period, as defined by an Investigator. Subjects who have autoimmune disease or immunodeficiency, or have a family history of related diseases. Subjects who have history of hypersensitivity or clinically significant allergic reaction to any drug, biologic, food or vaccine. Positive screening test results for human immunodeficiency virus (HIV-1/HIV-2) antibodies, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCVAb). Subjects who have received treatment with an investigational drug within 30 days or 5 times the half-life (whichever is longer) prior to screening. Subjects who have participated in any vaccine clinical study or have received any live vaccine within 3 months prior to the IMP administration or plan to receive live vaccines during the study period, and subjects who have received inactivated or attenuated vaccines 28 days prior to the IMP administration or plan to receive inactivated or attenuated vaccines within 2 months after the end of the study. If the subject has received any SARS-CoV-2 vaccine prior to screening, enrollment must be delayed until the biologic impact of the vaccine is stabilized, as determined by discussion between the investigator and the sponsor. Subjects who have taken drugs that may affect immune function within 6 months before screening, have received any monoclonal antibody or biological agent for treatment (for any illness) within the previous 3 months, and have previous treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals) within 7 days prior to IMP administration. Subjects whose daily consumption of coffee, tea and/or cola is more than 750 mL or 25 fl. oz in the last 30 days before enrollment. Subjects who have a positive urine alcohol test or urine drug test before enrollment. Subjects who have nicotine consumption (e.g., smoking, nicotine patch, nicotine chewing gum, or electronic cigarettes) within 3 months prior to screening and inability to refrain from nicotine consumption from screening until end of study. Female subjects who are pregnant or breastfeeding during the screening period and on admission. Subjects whose daily consumption of alcohol at the time of screening or at any time within the prior 2 months is more than 2 standard drinks, where 1 standard drink = 355 mL or 12 oz (1 can) of regular-strength (5%) beer; 150 mL or 5 oz wine; 45 mL or 1.5 oz liquor/spirits (40%). History of drug or alcohol abuse (as defined by the investigator), or addiction within 1 year prior to screening. Subjects who have undergone major surgery within 6 months of screening, or who will have elective surgery that will occur during the study period. Subjects who have donated either more than approximately 500 mL of blood (exclusive plasma donation) within 56 days (8 weeks) prior to screening or any plasma within 7 days (1 week) prior to screening. Subjects fails or is unwilling to abstain from strenuous physical activities for at least 48 hours prior to IMP administration and throughout the study. Subjects with any factors that would, in the Investigator's judgment, preclude them from participating in this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martin K Kankam, Doctor
Organizational Affiliation
Altasciences Clinical Kansas, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
AltaSciences Clinical Kansas, Inc
City
Overland Park
State/Province
Kansas
ZIP/Postal Code
66212
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

We'll reach out to this number within 24 hrs